IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10881658 B1

PDFFull Text
Date of Patent:
Jan. 05, 2021

Filed:

Dec. 11, 2019

Methods for treating huntington's disease

Applicant:

Ptc Therapeutics, Inc., South Plainfield, NJ (US);

Inventors:

Suresh Babu, Pennington, NJ (US);

Anuradha Bhattacharyya, Edison, NJ (US);

Seongwoo Hwang, Edison, NJ (US);

Minakshi Jani, Iselin, NJ (US);

Young-choon Moon, Belle Mead, NJ (US);

Nadiya Sydorenko, Princeton, NJ (US);

Assignee:

PTC Therapeutics, Inc., South Plainfield, NJ (US);

Attorney:

Hoffmann & Baron, LLP

Primary Examiner:

Charanjit Aulakh

Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61K 31/506 (2006.01); A61K 31/433 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 401/12 (2006.01); C07D 417/14 (2006.01); C07D 417/04 (2006.01); C07D 487/04 (2006.01); C07D 401/04 (2006.01); C07D 409/14 (2006.01); C07D 487/10 (2006.01); C07D 237/20 (2006.01); C07D 471/10 (2006.01); C07D 413/14 (2006.01); C07D 487/08 (2006.01); C07D 405/12 (2006.01); C07D 403/10 (2006.01); C07D 471/08 (2006.01); C07D 403/12 (2006.01); C07D 417/10 (2006.01); C07D 417/12 (2006.01); A61K 31/50 (2006.01); A61K 31/415 (2006.01); A61P 25/28 (2006.01); A61K 31/4439 (2006.01); A61K 31/4709 (2006.01); A61K 31/501 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/5513 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/415 (2013.01); A61K 31/433 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/50 (2013.01); A61K 31/501 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/5513 (2013.01); A61P 25/28 (2018.01); C07D 237/20 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 417/10 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/08 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/10 (2013.01); G01N 33/6896 (2013.01); G01N 2800/2835 (2013.01);
Abstract

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Find Patent Forward Citations

Loading…